Janssen Signs an Option Agreement with Philogen to Discover Small Molecule Therapeutics
Shots:
- The collaboration will utilize Philochem’s DNA-encoded chemical library technology platform to identify small molecule compounds with ultra-high affinity for tumor-associated antigens that bind to specific targets
- Janssen will exercise its options to use these identified ligands as therapies for drug discovery and development activities
- Philogen’s focuses are to discover and develop targeted anti-cancer therapeutics which selectively assessable at the site of disease to help spare normal tissue
Click here to read full press release
Ref: Globe Newswire | Image: Janssen
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com